0000358654
Donate

Reimbursement status:
Full reimbursement

Cancer: Lymphocytic leukaemia

Indication:

Notice: This drug is not included in ESMO standard but it is taken to Oncoindex value, because it is reimbursed. Blinatumomab is indicated as monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL). Blinatumomab is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation.

Reimbursement information:

EPAR/SmPC

Drug programme

Details

ATC category :
L01XC
L01XC Monoclonal antibodies
EMA approval status :
Approved
EMA approval date :
2015-11-23
EMA conditional? :
No
EMA orphan? :
Yes
EMA biological? :
Yes